United Therapeutics (UTHR) Aandelenoverzicht
United Therapeutics Corporation houdt zich bezig met de ontwikkeling en commercialisering van producten om te voorzien in de onvervulde medische behoeften van patiënten met chronische en levensbedreigende ziekten in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor UTHR uit onze risicocontroles.
UTHR Community Fair Values
Create NarrativeSee what 60 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% ondergewaardeerd intrinsieke korting
5419.8%Revenue growth p.a.
6.2k
18
0
126
United Therapeutics Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$570.40 |
| 52 Week Hoogtepunt | US$607.89 |
| 52 Week Laag | US$272.12 |
| Bèta | 0.75 |
| 1 maand verandering | 0.023% |
| 3 maanden verandering | 21.49% |
| 1 Jaar Verandering | 93.62% |
| 3 jaar verandering | 166.39% |
| 5 jaar verandering | 191.88% |
| Verandering sinds IPO | 9,260.41% |
Recent nieuws en updates
UTHR: IPF And Pulmonary Hypertension Data Will Drive Balanced Future Expectations
Analysts lifted their fair value estimate for United Therapeutics to $519 from $471, citing updated assumptions around revenue growth, profit margins, and future P/E multiples. These updates were informed by a wave of higher Street price targets following encouraging IPF and pulmonary hypertension data and the planned soft mist treprostinil inhaler launch.United Therapeutics: The Future Lies With Manufactured Organs
Apr 22
UTHR: IPF Lung Data Will Shape Future Pulmonary Franchise Outlook
Analysts have lifted the implied fair value estimate for United Therapeutics from about $592 to roughly $644, as higher Street price targets supported by more constructive views on Tyvaso, ralinepag and TreSMI, and a slightly richer assumed future P/E multiple, feed into modestly stronger revenue growth and margin assumptions. Analyst Commentary Street research around United Therapeutics has turned more constructive, with several bullish analysts revisiting their models following clinical updates on ralinepag and the TETON-1 study, along with the introduction of the TreSMI soft mist inhaler and management's longer term revenue ambitions.Recent updates
UTHR: IPF And Pulmonary Hypertension Data Will Drive Balanced Future Expectations
Analysts lifted their fair value estimate for United Therapeutics to $519 from $471, citing updated assumptions around revenue growth, profit margins, and future P/E multiples. These updates were informed by a wave of higher Street price targets following encouraging IPF and pulmonary hypertension data and the planned soft mist treprostinil inhaler launch.United Therapeutics: The Future Lies With Manufactured Organs
Apr 22UTHR: IPF Lung Data Will Shape Future Pulmonary Franchise Outlook
Analysts have lifted the implied fair value estimate for United Therapeutics from about $592 to roughly $644, as higher Street price targets supported by more constructive views on Tyvaso, ralinepag and TreSMI, and a slightly richer assumed future P/E multiple, feed into modestly stronger revenue growth and margin assumptions. Analyst Commentary Street research around United Therapeutics has turned more constructive, with several bullish analysts revisiting their models following clinical updates on ralinepag and the TETON-1 study, along with the introduction of the TreSMI soft mist inhaler and management's longer term revenue ambitions.UTHR: Pulmonary Fibrosis Promise Will Ultimately Fall Short Of Expectations
United Therapeutics' analyst fair value estimate has shifted from $423 to $471 as analysts factor in recent TETON-1 and ralinepag data, updated profit margin assumptions, and a modestly higher future P/E. Analyst Commentary Street research around United Therapeutics has become more focused on the readthrough from TETON-1 in idiopathic pulmonary fibrosis, the Phase 3 ralinepag results in pulmonary arterial hypertension, and the planned soft mist inhaler for treprostinil.UTHR: IPF And PAH Data Plus New Inhaler Will Shape Outlook
The analyst fair value estimate for United Therapeutics has been raised from $572.00 to $592.25 as analysts factor in higher assumed revenue growth, slightly stronger profit margins, and supportive Street research that highlights upcoming idiopathic pulmonary fibrosis and pulmonary arterial hypertension catalysts, as well as the planned soft mist treprostinil inhaler. Analyst Commentary Recent Street research around United Therapeutics clusters around two big themes, the pulmonary arterial hypertension and idiopathic pulmonary fibrosis pipeline, and the shift toward next generation treprostinil delivery, including the soft mist inhaler.UTHR: Ralinepag Phase 3 Success And New Inhaler Will Drive Upside
Narrative Update: United Therapeutics (UTHR) The updated analyst price target for United Therapeutics has moved from $531.25 to $572.00. This reflects analysts' higher conviction in ralinepag following stronger than expected Phase 3 data, as well as the potential long term contribution from the planned treprostinil soft mist inhaler program.
The Organ Manufacturing Frontier: More Than Just a Pharma Play?
As of February 2026, United Therapeutics has solidified its position as a dominant force in the pulmonary arterial hypertension (PAH) market. The company’s "Tyvaso" franchise has seen a 22% year-over-year surge in adoption, particularly as the DPI (Dry Powder Inhaler) version takes market share from more invasive delivery methods.UTHR: Organ Manufacturing And Sector M&A Capital Will Support Future Upside
United Therapeutics' analyst price target edges higher to $645 from $600, as analysts point to a slightly higher fair value estimate of about $531 per share and a modestly adjusted future P/E assumption around 14x, even as they flag ongoing sector level capital and M&A crosscurrents. Analyst Commentary Analysts are updating their views on United Therapeutics as they reset expectations for both the company and the broader Biotech sector heading into 2026.UTHR: Organ Manufacturing Pipeline And Sector M&A Prospects Will Drive Future Upside
Analysts have nudged their price target higher for United Therapeutics, with updated assumptions pointing to a fair value of about $530.84 per share versus roughly $518.25 previously, supported by slightly higher projected revenue growth and a modestly richer future P/E multiple. Analyst Commentary Recent commentary has focused on what United Therapeutics might look like as the Biotech sector heads into 2026 with cautious optimism.
UTHR: Respiratory Franchise Execution And Xenotransplantation Progress Will Drive Future Upside
Analysts have raised their price target on United Therapeutics to US$645 from US$575, citing stronger expectations for Tyvaso and Yutrepia revenue, higher projected revenue growth and profit margins, and a lower assumed future P/E multiple, even with a slightly higher discount rate. Analyst Commentary Recent Street research on United Therapeutics has leaned positive, with several bullish analysts lifting their price targets and pointing to execution on key respiratory drugs as a central theme.UTHR: Pulmonary And IPF Pipeline Momentum Will Support Balanced Future Prospects
Analysts have lifted their blended price targets for United Therapeutics into a roughly US$525 to US$587 range, largely reflecting confidence in Tyvaso-driven Q3 revenue momentum, early Yutrepia uptake, and expectations that the broader pulmonary and IPF franchises and partnership optionality can support the company’s long-term earnings profile. Analyst Commentary Street research around United Therapeutics is clustered around higher price targets in the US$525 to US$587 range, with one firm trimming its target slightly while staying on the sidelines.UTHR: Future Pulmonary Fibrosis Upside Will Prove Overestimated
We are raising our fair value estimate for United Therapeutics to $423 per share from $320.81, as analysts lift price targets following another record Tyvaso quarter, a strong early Yutrepia launch, and growing conviction that pulmonary fibrosis and ex U.S. partnership opportunities can materially accelerate revenue growth and support higher long term margins. Analyst Commentary Street research following the latest quarter has been broadly constructive, with several firms lifting price targets on the back of record Tyvaso performance and a better than expected Yutrepia launch.UTHR: Resilient Core And Clinical Milestones Will Support Balanced Prospects Ahead
The analyst price target for United Therapeutics has increased by $5 to reflect continued strong Tyvaso performance, a robust IPF opportunity, and a resilient core business, according to analysts. Analyst Commentary Recent updates from Wall Street reflect a dynamic range of sentiment regarding United Therapeutics, with several notable price target adjustments following the latest quarterly results and clinical developments.UTHR: Record Clinical Data And Expanding Pipeline Will Support Balanced Outlook Ahead
United Therapeutics’ analyst price targets have increased, with the fair value estimate rising from $510.77 to $513.00. Analysts point to strong Tyvaso revenue growth, robust product launches, and long-term opportunities in idiopathic pulmonary fibrosis.UTHR: Recent Clinical Success Will Drive Expansion Into New Pulmonary Markets
United Therapeutics' analyst price target has increased from approximately $493 to $511, as analysts cite strong Tyvaso revenue growth, robust product launches, and positive trial data. These factors support improved profit expectations and future growth prospects.Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
The analyst price target for United Therapeutics has increased modestly by approximately $8 to $492.85. Analysts cite greater confidence in the company’s future sales and profit margins following recent positive clinical trial outcomes and updated research coverage.Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
United Therapeutics' analyst price target has climbed significantly, rising from approximately $467 to nearly $485 per share. Analysts cite robust Phase 3 results for Tyvaso in idiopathic pulmonary fibrosis and a strengthened outlook for future sales growth.Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
Analysts raised their price target for United Therapeutics to $466.82, citing strong TETON-2 Phase 3 data for Tyvaso in IPF that de-risk future revenue, support peak sales projections, and heighten confidence in market exclusivity and regulatory approvals. Analyst Commentary Bullish analysts raised price targets significantly following strong Phase 3 TETON-2 data for Tyvaso in idiopathic pulmonary fibrosis (IPF), with the drug meeting primary and key secondary endpoints and demonstrating competitive, clinically meaningful efficacy.United Therapeutics Corporation (NASDAQ:UTHR) Surges 38% Yet Its Low P/E Is No Reason For Excitement
Sep 03
Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
United Therapeutics’ consensus price target has been raised from $380.57 to $399.90, reflecting heightened analyst optimism following positive Phase 3 TETON-2 Tyvaso IPF results that signal a multibillion-dollar sales opportunity and improved revenue outlook despite competitive and litigation risks. Analyst Commentary Bullish analysts increased price targets sharply following "surprisingly positive" Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis (IPF), citing clinically meaningful FVC benefit, strong statistical significance, and a competitive efficacy profile compared to pipeline peers.Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Jul 22Does United Therapeutics (NASDAQ:UTHR) Have A Healthy Balance Sheet?
May 11United Therapeutics: A Unique Business With High Margins And Expansion Potential
Feb 25United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14
Innovative Biotech Products Pave The Way For A Future Revenue Surge And Market Leadership
Advancements in treatments for pulmonary hypertension and fibrosis, and pioneering Xenotransplantation products, promise to lead market growth and address unmet medical needs.United Therapeutics: Economics Support Compounding Ability
Aug 20United Therapeutics: Exciting Company With A Big Problem
Jun 02Rendement voor aandeelhouders
| UTHR | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.6% | -2.5% | 0.8% |
| 1Y | 93.6% | 26.8% | 27.7% |
Rendement versus industrie: UTHR overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 26.8 % opleverde.
Rendement versus markt: UTHR overtrof de US markt, die het afgelopen jaar een rendement opleverde van 27.7 %.
Prijsvolatiliteit
| UTHR volatility | |
|---|---|
| UTHR Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stabiele aandelenkoers: UTHR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van UTHR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1996 | 1,400 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation houdt zich bezig met de ontwikkeling en commercialisering van producten om tegemoet te komen aan de onvervulde medische behoeften van patiënten met chronische en levensbedreigende ziekten in de Verenigde Staten en daarbuiten. Het biedt Tyvaso DPI, een geïnhaleerd droog poeder via voorgevulde patronen en patronen voor eenmalig gebruik; vernevelde Tyvaso, een geïnhaleerde oplossing via ultrasone vernevelaar; Remodulin (treprostinil) injectie voor de behandeling van patiënten met pulmonale arteriële hypertensie om de symptomen die gepaard gaan met inspanning te verminderen; Orenitram, een tabletvorm van treprostinil, om de ziekteprogressie te vertragen en de inspanningscapaciteit bij PAH-patiënten te verbeteren; en Adcirca, een orale PDE-5-remmer om de inspanningscapaciteit bij PAH-patiënten te verbeteren. Het verkoopt ook Unituxin (dinutuximab)-injectie, een monoklonaal antilichaam voor hoog-risico neuroblastoom; en Remunity Pump, dat een pomp en aparte controller voor Remoduline bevat.
United Therapeutics Corporation Samenvatting
| UTHR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$25.04b |
| Inkomsten(TTM) | US$1.33b |
| Inkomsten(TTM) | US$3.18b |
18.7x
Koers/Winstverhouding7.9x
P/S-verhoudingIs UTHR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| UTHR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$3.18b |
| Kosten van inkomsten | US$384.40m |
| Brutowinst | US$2.80b |
| Overige uitgaven | US$1.46b |
| Inkomsten | US$1.33b |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
May 06, 2026
| Winst per aandeel (EPS) | 30.45 |
| Brutomarge | 87.92% |
| Nettowinstmarge | 41.94% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde UTHR op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/01 10:23 |
| Aandelenkoers aan het einde van de dag | 2026/05/01 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
United Therapeutics Corporation wordt gevolgd door 34 analisten. 14 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Birchenough | Barclays |
| Derek Taller | Benchmark Company |